4D Molecular Therapeutics (NASDAQ:FDMT) Insider Scott Bizily Sells 9,810 Shares

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider Scott Bizily sold 9,810 shares of the stock in a transaction dated Tuesday, June 23rd. The stock was sold at an average price of $12.00, for a total transaction of $117,720.00. Following the transaction, the insider owned 8,617 shares in the company, valued at approximately $103,404. The trade was a 53.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

4D Molecular Therapeutics Price Performance

Shares of NASDAQ:FDMT traded down $0.10 during trading hours on Thursday, hitting $11.52. The company’s stock had a trading volume of 984,926 shares, compared to its average volume of 788,707. 4D Molecular Therapeutics, Inc. has a 52 week low of $3.68 and a 52 week high of $12.34. The company has a market capitalization of $602.27 million, a price-to-earnings ratio of -4.48 and a beta of 2.75. The firm’s fifty day moving average price is $9.50 and its 200 day moving average price is $9.13.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its quarterly earnings data on Thursday, May 7th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). The business had revenue of $3.05 million for the quarter, compared to the consensus estimate of $2.59 million. 4D Molecular Therapeutics had a negative net margin of 182.34% and a negative return on equity of 36.83%. On average, equities research analysts predict that 4D Molecular Therapeutics, Inc. will post -3.8 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on FDMT. Chardan Capital reiterated a “buy” rating and issued a $26.00 price target on shares of 4D Molecular Therapeutics in a report on Thursday, March 19th. Royal Bank Of Canada raised their price objective on 4D Molecular Therapeutics from $32.00 to $35.00 and gave the company an “outperform” rating in a research report on Thursday, March 19th. Wall Street Zen lowered 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. HC Wainwright reiterated a “buy” rating and issued a $36.00 target price on shares of 4D Molecular Therapeutics in a report on Friday, March 20th. Finally, Jefferies Financial Group restated a “buy” rating and issued a $21.00 price target (down from $40.00) on shares of 4D Molecular Therapeutics in a report on Monday, March 30th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, 4D Molecular Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $29.88.

Institutional Investors Weigh In On 4D Molecular Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Wexford Capital LP acquired a new stake in 4D Molecular Therapeutics in the third quarter worth about $41,000. Daiwa Securities Group Inc. raised its position in shares of 4D Molecular Therapeutics by 3,362.0% in the 4th quarter. Daiwa Securities Group Inc. now owns 6,370 shares of the company’s stock valued at $48,000 after purchasing an additional 6,186 shares during the last quarter. Susquehanna Portfolio Strategies LLC purchased a new position in shares of 4D Molecular Therapeutics in the 4th quarter valued at approximately $77,000. Martingale Asset Management L P boosted its stake in 4D Molecular Therapeutics by 12.4% in the 4th quarter. Martingale Asset Management L P now owns 11,775 shares of the company’s stock worth $88,000 after purchasing an additional 1,303 shares in the last quarter. Finally, Gabelli Funds LLC acquired a new stake in 4D Molecular Therapeutics in the 4th quarter worth approximately $90,000. 99.27% of the stock is currently owned by hedge funds and other institutional investors.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.